IDEAYA Biosciences, Inc.
IDYA
Rang in Aktien
#4746
IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to... IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to identifying and advancing targeted therapies, particularly leveraging the concept of synthetic lethality. The firm aims to develop specific treatments for patient groups selected through molecular diagnostic methods. At the forefront of its clinical efforts are two investigational drugs. IDE397, a methionine adenosyltransferase 2a (MAT2A) blocking agent, is currently in early-stage (Phase I) trials for solid tumors exhibiting methylthioadenosine phosphorylase (MTAP) deletions. Its second primary candidate, IDE196, a protein kinase C (PKC) inhibitor, is progressing through Phase I/II studies, targeting genetically defined cancers characterized by GNAQ or GNA11 gene mutations. Beyond its clinical pipeline, IDEAYA's earlier-stage portfolio includes several synthetic lethality programs. These encompass a PARG inhibitor designed to address tumors with specific genetic or molecular biomarkers, Pol Theta inhibitors aimed at cancers presenting with BRCA or other homologous recombination deficiency (HRD) mutations, and WRN inhibitors for tumors demonstrating high microsatellite instability (MSI-H). The company also engages in significant collaborations. It has a joint research effort with Cancer Research UK and the University of Manchester, focusing on small molecule inhibitors of Poly (ADP-ribose) glycohydrolase. Furthermore, IDEAYA maintains a partnership with Pfizer Inc. for the clinical development and supply in Phase I/II trials across metastatic uveal melanoma, skin melanoma, and other solid tumors, alongside a strategic alliance with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was established in 2015 and operates from its headquarters in South San Francisco, California.
Aktienkurs
$32.83
Zuletzt synchronisiert: 2026-10-16
Marktkapitalisierung
$3.17B
Veränderung (1 Tag)
-3.01%
Veränderung (1 Jahr)
12.20%
Land
US
Handel IDEAYA Biosciences, Inc. (IDYA)
Kategorie
Healthcare
Operative Marge für IDEAYA Biosciences, Inc. (IDYA)
Operative Marge zum October 2026 TTM: -92.66%
Laut den neuesten Finanzberichten und dem Aktienkurs von IDEAYA Biosciences, Inc. beträgt die aktuelle operative Marge (TTM) -92.66%. Am Ende des Jahres 2023 lag die operative Marge bei -574.85%.
Historie der operativen Marge von IDEAYA Biosciences, Inc. von 2017 bis 2026
Operative Marge zum Jahresende
| Jahr | Operative Marge | ändert |
|---|---|---|
| 2026 (TTM) | -92.66% | -98.02% |
| 2024 | -4,671.07% | 712.57% |
| 2023 | -574.85% | 368.42% |
| 2022 | -122.72% | -31.79% |
| 2021 | -179.91% | -0.55% |
| 2020 | -180.90% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | 0.00% |
Operative Marge vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Operative Marge | Differenz der operativen Marge | Land |
|---|---|---|---|
| 38.59% | -100.42% |
US
|
|
| -149.01% | -98.39% |
US
|
|
| 25.57% | -100.28% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -100.31% |
NL
|
Was ist die operative Marge eines Unternehmens?
Die operative Marge ist ein wichtiger Indikator zur Bewertung der Rentabilität eines Unternehmens. Höhere operative Margen sind in der Regel besser, da sie zeigen, dass ein Unternehmen seine Produkte oder Dienstleistungen mit deutlichem Gewinn über den Produktionskosten verkauft. Die operative Marge wird berechnet, indem der Gewinn des Unternehmens durch seinen Umsatz geteilt wird.